精神分裂症患者血清IL-1β、BDNF的表达与临床疗效的关系

Expression of Serum IL-1βand BDNF in Patients with Schizophrenia and Its Correlation with Clinical Efficacy

目的:探讨血清白细胞介素-1β(IL-1β)、脑源性神经营养因子(BDNF)的表达水平与精神分裂症患者临床疗效的关系。方法:本研究采用前瞻性队列研究方法,选取2019年1月-2021年12月宜春市第三人民医院收治的84例精神分裂症患者,所有患者均接受4周的跟踪治疗。调查所有受试对象临床资料并记录,应用Spearman分析精神分裂症患者血清IL-1β、BDNF与临床疗效的相关性,采用logistic回归分析影响精神分裂症患者疗效的影响因素。结果:治疗期间,84例精神分裂症患者中,中途退出4例,最终80例患者完成治疗;治疗4周,80例患者中显效10例,显著进步26例,好转28例,无效16例;治疗无效组精神分裂症患者血清IL-1β高于治疗有效组,血清BDNF低于治疗有效组,差异均有统计学意义(P<0.05);经Spearman相关性检验,结果显示,精神分裂症患者血清IL-1β水平与临床治疗效果呈正相关(rs=0.617,P<0.001),血清BDNF与临床治疗效果呈负相关(rs=-0.562,P<0.001);后进一步经logistic回归分析,结果显示,血清IL-1β水平为精神分裂症患者临床治疗无效的危险因素,BDNF水平为精神分裂症患者临床治疗无效的保护因素(P<0.05)。结论:精神分裂症患者血清IL-1β、BDNF表达与临床疗效存在一定关系,且高血清IL-1β水平、低BDNF水平提示治疗无效风险较高。

Objective:To explore the relationship between the expression levels of serum interleukin-1β(IL-1β)and brain-derived neurotrophic factor(BDNF)and the clinical efficacy of schizophrenia patients.Method:In this study,84 patients with schizophrenia admitted to Yichun Third People's Hospital from January 2019 to December 2021 were selected used prospective cohort study.All patients were followed up for 4 weeks.Clinical data of all subjects were investigated and recorded,the correlation between serum IL-1β,BDNF and clinical efficacy in patients with schizophrenia were analyzed by Spearman,and the influencing factors of the curative effect of schizophrenia patients were analyzed by logistic regression.Result:During the treatment period,among the 84 schizophrenic patients,4 cases withdrew halfway,and finally 80 patients completed the treatment.After 4 weeks of treatment,10 of the 80 patients were apparent effect,26 were significantly improved,28 were improved,and 16 were ineffective.The serum IL-1βin the treatment ineffective group was higher than that in the treatment effective group,and the serum BDNF was lower than that in the treatment effective group,the differences were statistically significant(P<0.05).The results of Spearman showed that the level of serum IL-1βin patients with schizophrenia was positively correlated with clinical treatment efficacy(rs=0.617,P<0.001),and serum BDNF was negatively correlated with clinical treatment efficacy(r s=-0.562,P<0.001).logistic regression analysis showed that serum IL-1βlevel was risk factor for clinical treatment failure in patients with schizophrenia,and BDNF level was protective factor for clinical treatment failure in patients with schizophrenia(P<0.05).Conclusion:The expression of serum IL-1βand BDNF in patients with schizophrenia are related to the clinical efficacy,and high serum IL-1βlevel and low BDNF level indicate high risk of treatment failure.